Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Koninklijke Philips NV — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.43 (market cap $29.60B), while Koninklijke Philips NV trades at $26.82 (market cap $26.58B). The key difference: Alnylam Pharmaceuticals, Inc. and Koninklijke Philips NV are close in size by market cap, and Koninklijke Philips NV pays a 3.75% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | PHG | |
|---|---|---|
Market Cap | $29.60B | $26.58B |
Sector | Health | Health |
52-Week High | $491.22 | $32.91 |
52-Week Low | $205.48 | $25.02 |
Enterprise Value | $27.56B | $33.13B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
PHG trades at $26.86, down 0.3% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after previous losses. Recent news highlights Exor's potential stake increase to 22% and FDA clearances for new medical devices, while analyst sentiment remains mixed with 41% buy ratings.
The outlook appears cautiously optimistic with solid earnings momentum and institutional accumulation, though risks include order intake volatility and competitive pressures. The stock offers value characteristics with reasonable P/E of 20.5 and strong cash flow generation, but investors should monitor execution on growth initiatives and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
